A deep learning model achieved up to 98% accuracy in distinguishing autistic from neurotypical participants, providing clear insights into brain regions most influential to its decisions. The model could benefit autistic people and clinicians by offering accurate and explainable results to inform assessment and support.
A cohort study reveals oral bacteria and fungi as significant risk factors for pancreatic cancer development. The findings suggest that oral microbiota may serve as biomarkers to identify individuals at high risk of pancreatic cancer, potentially contributing to personalized prevention strategies.
Researchers at Salk Institute and UC San Diego have identified a unique sugar called HSAT as a potential therapeutic target for slowing tumor progression and metastasis in pancreatic ductal adenocarcinoma. Boosting HSAT levels may slow the formation and spread of pancreatic cancer, leading to improved survival rates among patients.
A Japanese study has identified four distinct patterns of immune response after COVID-19 vaccines, with a 'rapid-decliner' group experiencing faster decline in antibody levels. Monitoring changes in antibody levels may help identify individuals at greater risk of infection and inform more effective vaccination strategies.
The VasCog-2-WSO criteria update provide operationalization and guidance on neuroimaging and fluid biomarkers for VCID diagnosis. This new standard aims to facilitate diagnostic consistency among clinicians and researchers worldwide.
A recent study identifies C1orf122 as a novel biomarker for hepatocellular carcinoma (HCC) progression and prognosis. C1orf122 promotes HCC via the SRPK1-PI3K/AKT/GSK3β axis, enhancing cell proliferation, suppressing apoptosis, and facilitating cell migration.
Researchers discovered elevated TSPO levels in the brain of genetically engineered mouse models and human patients with familial Alzheimer's disease, indicating a potential biomarker for early detection. The study aims to explore how blocking or enhancing TSPO could halt disease progression.
A new study published in Clinical Chemistry and Laboratory Medicine has developed a practical tool to support harmonization and quality improvement in vitamin D testing. The multicentre study evaluates the measurement uncertainty of various 25-(OH)D assays and their ability to detect physiologically relevant changes over time.
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
Researchers have identified two molecular targets, HER2 and CD24, as promising candidates for new nuclear diagnostics and therapeutics for endometrial cancer. These targets may help clinicians identify patients likely to respond to targeted therapies, offering new hope for those with disseminated or recurrent disease.
A recent study identifies four novel proteomic subtypes of GSRCC: Metabolism, Microenvironment Dysregulation, Migration, and Proliferation. Key prognostic biomarkers PRDX2 and DDX27 were also identified, with PRDX2 linked to favorable prognosis and DDX27 associated with poor survival outcomes.
Researchers at Kennedy Krieger Institute have developed biomarkers to help identify children with Sturge-Weber syndrome at risk of developing the condition. These tools can monitor disease progression and guide individualized treatment plans, potentially changing a child's development trajectory.
Researchers developed Vesalius to interpret complex data on cancer cell interactions, leading to potential discoveries in treating hard-to-treat cancers. The tool analyzes whole tissue architecture to identify predictive biomarkers and inform treatment options based on individual disease types.
A team of scientists has unveiled a MoS2-based phototransistor that sets new records in optical gain and sensitivity. The device detects light pulses containing tens of photons and identifies disease biomarkers at attomolar concentrations, outperforming current gold standard assays.
Researchers have developed a self-powered microneedle patch that can monitor biomarkers without drawing blood or relying on external devices. The patch uses dermal interstitial fluid (ISF) as a cleaner sample, which contains similar biomarkers to blood and doesn't require processing before testing.
A new study will investigate whether low levels of the lung protein CC16 in childhood can predict who will develop early chronic obstructive pulmonary disease (COPD) later in life. The five-year study aims to identify children at risk for early COPD and potentially intervene to prevent lung disease.
CISD1 expression linked to poor clinical outcomes, increased stemness levels, and tumor aggressiveness in multiple cancers. The gene's role in cellular bioenergetics also highlights its potential as a prognostic marker.
Researchers have developed an AI system that can recognize the early warning stages of laryngeal cancer from voice recordings. By analyzing variations in tone, pitch, and volume, the AI can distinguish between voices with benign vocal fold lesions and those with cancer. The study's findings offer a promising breakthrough for non-invasi...
Researchers at Arizona State University have developed a rapid and accurate diagnostic test called NasRED that can detect diseases like COVID-19 with high sensitivity. The test uses tiny gold nanoparticles to identify disease-related proteins in a sample of bodily fluid, providing lab-quality accuracy without expensive equipment.
A new study has identified a genetic biomarker that predicts which multiple sclerosis patients will respond well to treatment with glatiramer acetate. This allows for personalized therapy decisions to be made before starting treatment, with those carrying the HLA-A*03:01 gene variant showing significant clinical benefits.
Researchers identify key symptom categories and biomarkers for anti-NMDAR encephalitis, a rare autoimmune brain condition. Clinical manifestations suggest the presence of anti-NMDAR encephalitis through NMDA antibody checks, uric acid levels, C-reactive protein, and thyroid-related hormones.
The study identified significant alterations in chromatin accessibility of cis-regulatory elements associated with AML differentiation, linked to mutations in the WT1 transcription factor gene. These changes led to reduced chromatin accessibility and downregulation of target genes, promoting AML proliferation.
Researchers have developed a groundbreaking method to observe lysosomes in live suspended cells—quantitatively, in 3D, and without the use of chemical labels. The technology uses holographic tomography in flow cytometry configuration (HTFC) to identify morphological and spatial lysosomal changes in models of lysosomal storage diseases.
The project aims to develop novel, interpretable biomarkers using advanced artificial intelligence to overcome limitations in current diagnostic tools. The team will integrate multi-modal data and biomechanics for better diagnosis and tracking of chronic obstructive pulmonary disease (COPD).
A recent study has found that rheumatoid arthritis (RA) is a causal factor for idiopathic pulmonary fibrosis (IPF), while IPF is not causally related to RA. The research also identified shared biomarkers, including CCL2 and CXCL2, which were significantly elevated in RA patients.
A new deep learning model, MSI-SEER, achieves high accuracy in predicting microsatellite instability-high tumors and their responsiveness to immunotherapy. The model combines tumor MSI status with stroma-to-tumor ratio for highly accurate ICI response prediction.
Researchers at Brown University have identified a brain-based biomarker that can predict mild cognitive impairment development into Alzheimer's disease. They used a custom-built tool to analyze electrical activity from neurons and found distinct differences in beta events between patients who developed the disease and those who did not.
The journal is seeking high-quality submissions that explore the potential of voice and speech analysis in diverse medical applications. Submissions focus on acoustic and voice analysis techniques, voice or vocal phenotyping, and vocal biomarkers in health and medicine.
A new study found that two simple blood markers—eGFRdiff and GDF-15 levels—can independently predict kidney disease progression and mortality in people with diabetes. Patients with lower eGFRdiff values faced a higher risk of chronic kidney disease, while those with elevated GDF-15 levels were at increased risk of death.
A groundbreaking study found significant mitochondrial cardiolipin dysregulation in patients with bortezomib-induced peripheral neuropathy. The researchers identified diosmin as a promising candidate for targeting this condition, providing new avenues for therapeutic intervention.
Researchers have identified a novel diagnostic tool that can predict patient outcomes for head and neck squamous cell carcinoma. The LIMA1-alpha protein reliably identifies patients who can be cured with surgery alone, avoiding unnecessary oncological treatments.
Aging and depression are linked to complex brain-body communication, with organs aging at different rates and influencing disease susceptibility. Dr. Hamilton Oh's research reveals how immune cells and metabolic organs amplify or dampen mood symptoms, offering novel therapeutic targets.
Researchers highlight microRNAs as crucial biomarkers for diagnosing and monitoring soft tissue sarcomas, with potential for precision medicine. MicroRNAs could help distinguish between tumor types and guide treatment decisions.
The Lundquist Institute has received a $11 million NIH grant to revolutionize the diagnosis and treatment of mucormycosis, a deadly fungal infection. The MUCOR-ADVANCE initiative aims to develop rapid diagnostic tests and immune-based therapies to save lives.
A newly developed AI-based tool uses protein expression to create a stemness index that analyzes tumor similarity to pluripotent stem cells. The model predicts tumor aggressiveness and identifies potential targets for new therapies, offering hope for improved cancer treatment.
A Finnish population study reveals that middle-aged individuals can have high levels of blood-based biomarkers associated with Alzheimer's disease. The study found a link between kidney disease and higher biomarker levels in middle age, as well as an association between the APOE ε4 gene and older age biomarker concentrations. Further r...
A new review leverages cutting-edge spatial transcriptomics and single-cell omics to identify robust predictive biomarkers for tumor immunotherapy. Representative case studies highlight the potential of spatially resolved markers to guide immunotherapy decisions and predict irAE risk.
A Phase II study found that 87% of patients with stage III melanoma remained alive and disease-free four years after treatment with nivolumab and relatlimab. Researchers identified unique biomarkers associated with better outcomes, including high TIGIT levels and low B7-H3 levels.
The study identified a rare genetic alteration associated with high levels of the ADAM10 protein, which plays a role in breaking down beta-amyloid precursor protein. The researchers aim to develop a panel of prognostic biomarkers to differentiate Alzheimer's disease from other types of dementia.
Researchers at UChicago have developed a more sensitive liquid biopsy test that uses RNA to detect the earliest stages of colorectal cancer with 95% accuracy. The test analyzes RNA modification levels in blood samples, which remain stable regardless of sample preparation.
A new blood biomarker, p-tau217, has been identified as a potential predictor of Alzheimer's disease progression. This marker shows promise in identifying individuals at higher risk of developing the disease, allowing for early intervention and targeted treatment.
Researchers analyzed viral loads during early infection to predict disease progression and developed a method to identify patients at risk of severe symptoms. The study suggests that patients with high viral loads are more likely to experience long-lasting skin lesions and severe symptoms.
A Nagoya University group created a sandwich ELISA technique to accurately measure polysialic acid levels in the blood of patients with psychiatric disorders. The technique uses antibodies that minimize non-specific binding, resulting in increased accuracy.
Researchers at the University of Illinois developed cryosoret nanoassemblies that enhance fluorescence signals, reducing detection limits for biomarkers. The new platform offers dual-mode interaction between electric and magnetic components of light, promising highly sensitive and tunable biosensing systems.
A unique luminescent probe using terbium has been developed to detect β-glucuronidase, an enzyme that can aid in liver cancer diagnosis. The sensor's sensitivity and accuracy are comparable to conventional methods but at a lower cost, making it suitable for resource-limited settings.
Scientists from Pusan National University discovered a genetic biomarker, FCGBP, that is strongly linked to bronchiolitis obliterans syndrome and poor outcomes following lung transplantation. The finding may help identify high-risk patients and devise timely immunosuppressive treatments.
A study by researchers at the University of Gothenburg found that newborn babies and patients with Alzheimer's disease share elevated levels of phosphorylated tau, specifically p-tau217. In newborns, this protein reflects a healthy mechanism for brain development, while in Alzheimer's patients, it indicates disease progression.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
The study presents ImmunoCheckDB, a web platform that bridges a critical gap in existing resources by enabling pan-cancer exploration of immune checkpoint inhibitor therapies through combined meta-analytical and multiomic approaches. It curates 173 studies involving 93,234 individuals across 18 cancer types and 30 ICI regimens.
A study found that individuals with short leukocyte telomere lengths are more likely to develop age-related brain diseases such as stroke, dementia, and late-life depression. However, those with healthy lifestyle habits may modify the effects of shorter telomeres.
Researchers developed a blood-based proteomic score to predict healthy aging and age-related diseases. A lower score is associated with higher mortality and disease risk, offering a powerful tool for understanding biological aging.
Researchers developed an improved biological ageing clock, LinAge2, that offers doctors a practical way to assess how quickly a person is ageing and what can be done to slow it down. The new algorithm-powered tool outperforms other clinical models in predicting long-term mortality and health outcomes.
Researchers found no significant decline in taurine levels with age across humans, monkeys, and mice, suggesting it may not be a reliable marker of aging. Instead, individual physiological contexts shaped by genetic, nutritional, and environmental factors influence its impact.
A recent study found that MET mutations are associated with enhanced tumor immunogenicity, increased immune cell infiltration, and improved response rates to immune checkpoint blockade. Certain single base substitutions identified as robust predictive biomarkers for survival in pan-cancer immunotherapy.
The new device, nicknamed ABLE, uses a natural process to condense airborne biomarkers into water droplets, allowing for accurate detection at low concentrations. This technology has immediate applications in hospitals and neonatal units, offering a less invasive alternative to blood draws.
The annual Alzheimer's disease drug development pipeline report, led by Dr. Jeffrey Cummings, highlights an increase in active clinical trials and promising drugs, offering reason for optimism. The report assesses 138 drugs currently being studied and notes the growing importance of biomarkers in clinical trials.
Researchers identified C5aR1 as a novel prognostic biomarker and potential therapeutic target for treating metastatic skin cancer. Elevated C5aR1 presence suggests increased metastasis risk and poor survival in patients with cutaneous squamous cell carcinoma.
A team of researchers from CRCHUM has identified a set of biomarkers in blood samples that could help diagnose Parkinson's disease. The study found that immune cells in the blood were activated and overexpressed genes associated with stress responses in patients with Parkinson's, forming a unique genetic signature.
Researchers discovered biomarkers in gut bacteria and metabolites that can help diagnose and treat gastrointestinal diseases. The study found that certain biomarkers could predict multiple diseases, including gastric cancer and inflammatory bowel disease.
Researchers have developed a machine learning tool that identifies metabolism-related molecular profile differences between colorectal cancer patients and healthy individuals. The tool, called PANDA, shows promise as a noninvasive method of diagnosing colorectal cancer and monitoring disease progression.